DOD participated in COVID-19 antibody treatment trial
On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical…
Rising mortality as Africa marked one year of COVID-19
On Feb. 11, 2021, the WHO announced that COVID-19 cases and deaths surged in Africa as more contagious…
ImmunityBio and NantKwest announced FDA authorization to study hAd5 T-cell COVID-19 vaccine
On Feb. 11, 2021, ImmunityBio and NantKwest announced they had received FDA authorization to expand Phase I testing…
Relief confirmed release of preliminary findings from phase 2b/3 trial of intravenous RLF-100ﾙ (aviptadil)
On Feb. 10, 2021, RELIEF THERAPEUTICS announced the release of preliminary results from the phase 2b/3 trial of…
XPhyto added mescaline production to psychedelic medicine programs
On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to…
BioNTech updated vaccine production manufacturing site in Marburg, Germany
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
FDA authorized Eli Lilly’s monoclonal antibodies for treatment of COVID-19
On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab…
Oxford Immunotec entered MOU with Green Cross to market T-SPOT Discovery SARS-CoV-2 Kit in South Korea
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
Eiger announced ILIAD study results of peginterferon lambda in COVID-19 published in Lancet
On Feb. 8, 2021, Eiger BioPharmaceuticals announced that the final results from the Phase 2 ILIAD (Interferon Lambda…
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
Repligen and Navigo Proteins announced the launch of affinity resin for the purification of COVID-19 vaccines
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they had completed the development and initiated the…
US COVID-19 infections nearly three times greater than reported, UTSW model estimated
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
CureVac and UK Government announced collaboration on development of vaccines against SARS-CoV-2 variants
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
The Wellcome Sanger Institute announced sequencing 136,383 Coronavirus genomes in the UK
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
Oxford University vaccine effective against major B117 ﾑKentﾒ coronavirus strain circulating in the UK
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxfordﾒs…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
The US Department of Defense announced use of masks and other public health measures
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
XPhyto announced psychedelic pharmaceutical production agreement
On Feb. 3, 2021, XPhyto announced an agreement with Applied Pharmaceutical Innovation for the synthesis of pharmaceutical grade…
Vaxart announced positive preliminary data from phase 1 clinical trial evaluating oral COVID-19 tablet vaccine candidate
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
Dynavax and Serum Institute announced first participant dosed in trial evaluating Tdap vaccine adjuvanted with CpG 1018
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
Humanigen and Avid Bioservices entered Into cGMP manufacturing agreement for COVID-19 therapeutic
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
BD announced assay for identification of COVID-19 patients at increased risks of intubation available in Europe
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestﾙ 6-Color TBNK Reagent with…
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
GSK and CureVac announced JV to develop next generation mRNA COVID-19 vaccines
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ﾀ150m collaboration, building on their existing relationship, to…
SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…